In cancer, low PRDM3 expression and PRDM3 mutations can disrupt normal gene silencing and contribute to tumorigenesis, as observed in many leukemias and hepatocellular and ovarian carcinomas in which an alteration in its function negatively impacts tumor suppressor genes and promotes oncogenic processes [57]. This evidence concerns the gene MECOM and cancer.